转移性肾细胞癌的一线与二线治疗
本文通过PubMed和Embase检索截至2024年10月的文献并手工检索指南与会议记录,对转移性肾细胞癌系统治疗进行叙述性综述。一线可选免疫检查点抑制剂联合方案或酪氨酸激酶抑制剂,已有四种联合方案获国际批准;二线需标准化,TKI单用或联合依维莫司显示有前景的疗效,HIF2a抑制剂提供毒性谱更有利的新选择,早期进展后不建议ICI再挑战。
要点
- 一线治疗包括ICI联合方案或TKI,四种联合方案已获国际批准。
- 因缺乏头对头试验和标准化生物标志物,治疗决策依赖IMDC风险评分等因素。
- 早期进展后不建议ICI再挑战。
核心结论
- 为优化mRCC治疗选择,临床医生须仔细平衡疗效、毒性和患者偏好,尤其在一线与二线治疗转换时,以提供个体化治疗。
研究设计与样本
- 叙述性综述,检索PubMed和Embase并手工检索指南和会议记录,截至2024年10月,通过投票解决作者间分歧。
主要发现
- 一线治疗选择包括基于免疫检查点抑制剂(ICI)的联合方案或酪氨酸激酶抑制剂(TKI)。
- 四种联合方案已获国际批准。
- 许多患者在接受基于ICI的治疗后仍会出现疾病进展,需要进一步治疗。
- TKI单用或联合依维莫司显示有前景的疗效,HIF2a抑制剂提供毒性谱更有利的新选择。
关键数值与推荐
- 因缺乏头对头试验和标准化生物标志物,治疗决策依赖IMDC风险评分、功能状态、安全性特征、肉瘤样特征、免疫抑制剂使用及是否需要立即缓解等因素。
- 早期进展后不建议ICI再挑战。
临床怎么用
- 临床医生须仔细平衡疗效、毒性和患者偏好,尤其在一线与二线治疗转换时,以提供个体化治疗。
局限性
- 缺乏头对头试验和标准化生物标志物。
- 标准化二线方法的需求仍未满足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly in recent years, leading to improved outcomes. The aim of this review is to provide clinicians with a practical guide for selecting first- and second-line treatments on the basis of current evidence. METHODS: We critically evaluated systemic treatment strategies for mRCC. A comprehensive literature search was conducted in PubMed and Embase, alongside manual searches of guidelines and conference proceedings up to October 2024. A narrative review was performed to reach a consensus, with voting used to resolve differing opinions among authors. KEY FINDINGS AND LIMITATIONS: First-line treatment options include immune checkpoint inhibitor (ICI)-based combinations or tyrosine kinase inhibitors (TKIs). Four combination regimens have been approved internationally. Owing to the lack of head-to-head trials and standardized biomarkers, treatment decisions rely on factors such as International Metastatic RCC Database Consortium (IMDC) risk score, functional status, safety profiles, sarcomatoid features, use of immunosuppressive drugs, and need for immediate response. Despite advances, many patients will experience disease progression on ICI-based therapy, necessitating further treatment. The need for standardized second-line approaches remains unmet. TKIs, alone or with everolimus, show promising efficacy, while HIF2a inhibitors offer newer options with a favorable toxicity profile. Rechallenge with ICIs after early progression is not recommended. CONCLUSIONS AND CLINICAL IMPLICATIONS: For optimal mRCC treatment selection, clinicians must carefully balance efficacy, toxicity, and patient preferences, especially when transitioning between first- and second-line therapies, to provide individualized care.
引用
- Barragan-Carrillo R, Saad E, Saliby RM, et al. First and Second-line Treatments in Metastatic Renal Cell Carcinoma. Eur Urol. 2024. PMID: 39505582. doi:10.1016/j.eururo.2024.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。